Announced details
Regenerative medicine; research and clinical applications for a wide range of diseases
Cumulative 11,400 ASC contract processing cases (as of the end of July 2026). More than 130,000 cumulative cell and other processing cases
To be rolled out sequentially by partner medical institutions. Detailed relationship: Not disclosed
Certificate of Eligibility for Materials for Regenerative Medicine Products
Pharmaceuticals and Medical Devices Agency (PMDA)
Facility No.: FA3240004 (licensed facility for manufacturing specified cell-processed products and other materials)
Shibuya Cast 11F, 1-23-21 Shibuya, Shibuya-ku, Tokyo
The impact on the company’s results is expected to be minor.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Adipose-derived mesenchymal stem cell (ASC) contract processing service |
| Relationship with the Company | To be rolled out sequentially by partner medical institutions. Detailed relationship: Not disclosed |
| Launch date | November 2026 (scheduled; sequential rollout by some partner medical institutions) |
| Applicable area | Regenerative medicine; research and clinical applications for a wide range of diseases |
| Award/certification name | Certificate of Eligibility for Materials for Regenerative Medicine Products |
| Awarding / certifying body | Pharmaceuticals and Medical Devices Agency (PMDA) |
| Registration number and expiry date | Facility No.: FA3240004 (licensed facility for manufacturing specified cell-processed products and other materials) |
| Location | Shibuya Cast 11F, 1-23-21 Shibuya, Shibuya-ku, Tokyo |
| Usage history | Cumulative 11,400 ASC contract processing cases (as of the end of July 2026). More than 130,000 cumulative cell and other processing cases |
| Impact on Business Performance | The impact on the company’s results is expected to be minor. |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To reduce risks arising from materials of animal origin and lot-to-lot variation in raw materials, enhance and stabilize quality control, and eliminate the post-thaw washing and replacement steps, thereby reducing the workload at medical facilities and the risks of cell loss and contamination.